3Shiraishi T, Nakagawa Y, Takahashi C,et al. Susceptibilities of organisms isolated in the hospital to commontly used disinfectants. Hosp Pharm,1988,14∶377-381.
4Shiraishi T, Nakagawa Y. Review of disinfectant susceptibility of bacteria isolated in hospital to commonly used disinfectants. Pastgrad Med J,1993,69 (suppl 3)∶s70-s77.
5Khare M, Keady D. Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection [ J]. Expert Opin Pharmacother , 2003,4(2) : 165 - 177.
6Wu JA, Kusuma C, Mond JJ, et al. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces [ J ]. Antimicrob Agents Chemother, 2003,47 ( 11 ) :3407 - 3014.
7Walsh S,Kokai-Kun J,Shah A, et al. Extended nasal residence time of lysostaphin and an anti-staphylococcal monoclonal antibody by delivery in semisolid or polymeric carriers [J]. Pharmaceutic Res,2004,21(10) : 1770 - 1775.
8Fief C, Kokasi-Kun JF, Becker K, et al. In vitro activity of recombinant lysostaphin against staphylococcus aureus isolates from anterior nares and blood [ J]. Antimicrob Agents Chemother, 2003,47(11) :3613- 3615.
9Polak J, Latta PD, Blackburn P. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus [ J ]. Diagn Microbiol Infect Dis, 1993,17 (4) :265 - 270.
10Climo MW, Ehlert K, Archer GL. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus [J]. Antlmicrob Agent Chemother, 2001,45 (5) : 1431 - 1437.
